Charles River Laboratories International (NYSE:CRL) Downgraded by Bank of America to Neutral
Bank of America downgraded shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a buy rating to a neutral rating in a report issued on Wednesday, MarketBeat.com reports. The firm currently has $215.00 price target on the medical research company’s stock, down from their prior price target of $250.00. Other equities analysts have […]
6 Oct 03:28 · The Cerbat Gem